Morgan Stanley: Maintains "overweight" rating on TONGRENTANGCM (03613) with a target price lowered to HKD 12.8
Daiwa Securities downgrades Tong Ren Tang Guoyao (03613) earnings forecast for 2024-2030 by 6%-10%.
Morgan Stanley released a research report stating that following the announcement of TONGRENTANGCM (03613) first half performance in 2024, due to a decrease in sales, Morgan Stanley has lowered its profit forecast for the years 2024-2030 by 6%-10%. At the same time, the target price and scenario value of the company have decreased by 5%-8%. Specifically, the target price of TONGRENTANGCM has decreased by 5%, from HK$13.5 to HK$12.8, while still maintaining a "buy" rating.
Related Articles

US Stock Market Move | Biopharmaceutical company Maplight Therapeutics (MPLT.US) listed on the US stock market, with its stock price rising more than 15.8%.

US Stock Market Move | Strive (ASST.US) surged by 35% in the past 3 trading days, with a total increase of 92%.

The U.S. Department of Energy is partnering with AMD (AMD.US) to build two AI supercomputers to accelerate scientific breakthroughs in nuclear energy, cancer drugs, and more.
US Stock Market Move | Biopharmaceutical company Maplight Therapeutics (MPLT.US) listed on the US stock market, with its stock price rising more than 15.8%.

US Stock Market Move | Strive (ASST.US) surged by 35% in the past 3 trading days, with a total increase of 92%.

The U.S. Department of Energy is partnering with AMD (AMD.US) to build two AI supercomputers to accelerate scientific breakthroughs in nuclear energy, cancer drugs, and more.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025


